Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
NCT ID: NCT00231166
Last Updated: 2018-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2005-09-30
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
NCT03489525
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
NCT02431208
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
NCT01114048
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
NCT01421186
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
NCT01668719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCD122
HCD122
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCD122
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory or Relapsed Disease
* At least one prior treatment regimen
* Male or Female
* \>18 years of age
Exclusion Criteria
* Intracranial disease or epidural disease
* Clinically significant cardiac dysfunction or other significant organ dysfunction
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmeceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102
Boston, Massachusetts, United States
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer
New York, New York, United States
Oregon Health Sciences University
Portland, Oregon, United States
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102
Philadelphia, Pennsylvania, United States
Fred Hutchinson Cancer Research Center Dept. of FHCRC
Seattle, Washington, United States
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Prahran, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHCD122A2102
Identifier Type: -
Identifier Source: org_study_id
NCT00304109
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.